Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 315

1.

Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.

Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC.

Ann Surg. 2016 May 26. [Epub ahead of print]

PMID:
27232252
2.

Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.

Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, Lee HY, Rha SY.

Yonsei Med J. 2016 Jul;57(4):831-9. doi: 10.3349/ymj.2016.57.4.831.

3.

Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy.

Kim HR, Kim JH, Rhee Y, Lee H, Song SE, Kim C, Song S, Noh SH, Rha SY.

Oncology. 2016;90(5):248-54. doi: 10.1159/000445010. Epub 2016 Apr 13.

PMID:
27070835
4.

Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.

Kim MJ, Kim YS, Oh SY, Lee S, Choi YJ, Seol YM, Park MJ, Kim KH, Park LC, Kang JH, Hwang IG, Lee SI, Lim ST, Kim HS, Lim HY, Rha SY, Kim HJ.

Korean J Intern Med. 2016 Apr 6. doi: 10.3904/kjim.2015.162. [Epub ahead of print]

5.

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.

Kim JH, Lee JS, Kim EJ, Park KH, Kim KH, Yi SH, Kim HS, Cho YJ, Shin KH, Ahn JB, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Noh SH, Rha SY, Kim HS.

Oncotarget. 2016 Mar 21. doi: 10.18632/oncotarget.8240. [Epub ahead of print]

6.

Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.

Park JS, Kim HS, Bae YS, Cheong JH, Rha SY, Noh SH, Kim H.

Jpn J Clin Oncol. 2016 Mar 23. pii: hyw030. [Epub ahead of print]

PMID:
27008850
7.

Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Rha SY, Park Y, Song SK, Lee CE, Lee J.

Support Care Cancer. 2016 Mar 16. [Epub ahead of print]

PMID:
26984242
8.

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.

Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, Rha SY.

Cancer Res Treat. 2016 Feb 12. doi: 10.4143/crt.2016.018. [Epub ahead of print]

9.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

PMID:
26874885
10.

Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.

Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, Rha SY, Tsao H.

J Invest Dermatol. 2016 May;136(5):1002-11. doi: 10.1016/j.jid.2016.01.024. Epub 2016 Feb 15.

PMID:
26854490
11.

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.

Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M.

Ann Nucl Med. 2016 May;30(4):279-86. doi: 10.1007/s12149-016-1059-x. Epub 2016 Feb 2.

PMID:
26837515
12.

Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.

Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY.

Oncotarget. 2016 Feb 16;7(7):8055-66. doi: 10.18632/oncotarget.6977.

13.

Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity.

Noh HS, Hah YS, Ha JH, Kang MY, Zada S, Rha SY, Kang SS, Kim HJ, Park JY, Byun JH, Hahm JR, Shin JK, Jeong SH, Lee YJ, Kim DR.

Oncotarget. 2016 Jan 26;7(4):4632-46. doi: 10.18632/oncotarget.6728.

14.

Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK.

Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.

PMID:
26540173
15.

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.

Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim do H, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.

16.

Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference.

Baiocchi GL, D'Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, Marrelli D, Allum W, Berruti A, Chandramohan SM, Coburn N, Gonzàlez-Moreno S, Hoelscher A, Jansen E, Leja M, Mariette C, Meyer HJ, Mönig S, Morgagni P, Ott K, Preston S, Rha SY, Roviello F, Sano T, Sasako M, Shimada H, Schuhmacher C, So Bok-Yan J, Strong V, Yoshikawa T, Terashima M, Ter-Ovanesov M, Van der Velde C, Memo M, Castelli F, Pecorelli S, Detogni C, Kodera Y, de Manzoni G.

Gastric Cancer. 2016 Jan;19(1):15-20. doi: 10.1007/s10120-015-0513-0. Epub 2015 Jul 4.

PMID:
26140915
17.

Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study.

Park S, Noh YH, Rha SY, Kim WH, Cheon JH.

Intest Res. 2015 Jul;13(3):274-81. doi: 10.5217/ir.2015.13.3.274. Epub 2015 Jun 9.

18.

Leiomyosarcoma: investigation of prognostic factors for risk-stratification model.

Kim HJ, Cho YJ, Kim SH, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Roh JK, Kim KS, Choi YD, Shin KH, Kim HS.

Int J Clin Oncol. 2015 Dec;20(6):1226-32. doi: 10.1007/s10147-015-0847-y. Epub 2015 Jun 28.

PMID:
26123311
19.

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.

Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP.

Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. doi: 10.1007/s00280-015-2811-y. Epub 2015 Jun 24.

PMID:
26099969
20.

Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation.

Roh MR, Kim JM, Lee SH, Jang HS, Park KH, Chung KY, Rha SY.

J Dermatol. 2015 Sep;42(9):881-8. doi: 10.1111/1346-8138.12950. Epub 2015 Jun 5.

PMID:
26047064
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk